SCHEMBL372668

SCHEMBL372668

Fc1c(CBr)ccc(-c2ncco2)c1F

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.34
ADRA1D P25100 2/20 0.34
ADRA1B P35368 2/20 0.34
ADRA2A P08913 1/20 0.34
BRD4 O60885 1/20 0.34
HPGDS O60760 1/20 0.33
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
LTA4H P09960 1/20 0.32
PIN1 Q13526 1/20 0.31
ADORA3 P0DMS8 1/20 0.30
ADORA2A P29274 1/20 0.30
ADORA2B P29275 1/20 0.30
ADORA1 P30542 1/20 0.30
HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374357 0.75 ADRA1A (0.32) ADRA1AADRA1DADRA1BADRA2ABRD4
SCHEMBL372815 0.74 LTA4H (0.40) BRD4HPGDSLTA4H
SCHEMBL22053014 0.71 BRD4 (0.38) ADRA1AADRA1DADRA1BADRA2ABRD4
SCHEMBL12804460 0.70 CTSA (0.41) ADRA1AADRA1DADRA1BADRA2ABRD4
SCHEMBL25286035 0.68 NPC1 (0.40) ADRA1AADRA1DADRA1BADRA2ABRD4
SCHEMBL22041213 0.68 BRD4 (0.38) ADRA1AADRA1DADRA1BADRA2ABRD4
SCHEMBL6491170 0.68 LTA4H (0.40) BRD4HPGDSLTA4H
SCHEMBL7834048 0.67 ADRA1A (0.48) ADRA1AADRA1DADRA1BADRA2ABRD4
SCHEMBL11363800 0.66 BRD4 (0.57) ADRA1AADRA1DADRA1BADRA2ABRD4
SCHEMBL27836284 0.66 LTA4H (0.41) BRD4HPGDSLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408756-B1 ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2013-05-15 EP disclosed
EP-2408756-A1 ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES Bristol-Myers Squibb Company (US) 2012-01-25 EP disclosed
US-7977362-B2 Alpha-(N-benzenesulfonamido)cycloalkyl derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 2011-07-12 US disclosed
WO-2010108067-A1 ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-23 WO disclosed
US-20100240708-A1 Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives BRISTOL-MYERS SQUIBB COMPANY 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240708-A1 Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives BACE1, BACE2, APP ADRA1A 311/4885ADRA1D 390/4885ADRA1B 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.